The inconsistency between two major aneuploidy-screening platforms-single-nucleotide polymorphism array and next-generation sequencing-in the detection of embryo mosaicism

• Published in: BMC genomics 2022-01, Vol.23 (1), p.62-62, Article 62
• Main Authors: Chen, Dongjia, Xu, Yan, Ding, Chenhui, Wang, Yali, Fu, Yu, Cai, Bing, Wang, Jing, Li, Rong, Guo, Jing, Pan, Jiafu, Zeng, Yanhong, Zhong, Yiping, Shen, Xiaoting, Zhou, Canquan
• Format: Article
• Language: English
• Subjects: Accuracy; Age; Aneuploidy; Arrays; Biopsy; Births; Blastocyst; Blastocysts; Chromosomes; Clinical outcomes; Discordance; Embryos; Female; Gene polymorphism; Genetic screening; Genetic Testing; Genomics; High-Throughput Nucleotide Sequencing; Humans; Mosaicism; Mosaics; Multiple displacement amplification; Next-generation sequencing; Nucleotides; Platforms; Polymorphism; Polymorphism, Single Nucleotide; Pregnancy; Preimplantation Diagnosis; Preimplantation genetic testing for aneuploidies; Retrospective Studies; Screening; Single-nucleotide polymorphism; Single-nucleotide polymorphism array; Trophectoderm; Uterus
• ISSN: 1471-2164; 1471-2164
• DOI: 10.1186/s12864-022-08294-1

In preimplantation genetic testing for aneuploidy (PGT-A), appropriate evaluation of mosaic embryos is important because of the adverse implications of transferring embryos with high-level mosaicism or discarding those with low-level mosaicism. Despite the availability of multiple reliable techniques for PGT-A, data comparing the detection of mosaicism using these techniques are scarce. To address this gap in the literature, we compared the detection ability of the two most commonly used PGT-A platforms, next-generation sequencing (NGS) and the single-nucleotide polymorphism (SNP) array, for mosaic embryos. We retrospectively reviewed the data of PGT-A or preimplantation genetic testing for chromosomal structural rearrangements (PGT-SR) conducted at our center from January 2018 to October 2020, and selected blastocysts that underwent aneuploidy screening with both an SNP array and NGS. Trophectoderm biopsy, multiple displacement amplification (MDA), and aneuploidy screening with an SNP array were conducted on the enrolled blastocysts. When the SNP array indicated mosaicism, NGS was performed on the corresponding MDA product for verification. Among the 105 blastocysts diagnosed with mosaicism with the SNP array, 80 (76.19%) showed mosaicism in NGS, with complete and partial concordance rates of 47.62% (50/105) and 18.10% (19/105), respectively. The complete discordance rate of the two platforms was 34.29% (36/105). That is, 10.48% (11/105) of the blastocysts were diagnosed with completely different types of mosaicism with the two platforms, while 13.33% (14/105) and 10.48% (11/105) of the embryos diagnosed as showing mosaicism with SNP were detected as showing aneuploidy and euploidy with NGS, respectively. The consistency of NGS and the SNP array in the diagnosis of embryo mosaicism is extremely low, indicating the need for larger and well-designed studies to determine which platform is more accurate in detecting mosaic embryos.